ASAcampus is constantly at the forefront in developing new research. The latest is “Effect of NIR Laser Therapy by MLS‐MiS Source on Fibroblast Activation by Inflammatory Cytokines in Relation to Wound Healing” che si which aimed to study the anti-inflammatory activity of MiS, the ASA device capable of combining the synchronised action of MLS® Laser Therapy with the pulse power of Hilterapia®, from the cellular and molecular point of view.
The in-vitro study was carried out on human dermal fibroblasts exposed firstly to a mix of inflammatory cytokines (IL‐1β and TNF‐α) which subsequently underwent treatment with MiS.
Three types of samples were analysed:
After analysing the results, the researchers noted that the main pathways signalling inflammation were increased (or activated) by the mix of cytokines, whilst treatment with MiS lowered the levels, restoring basal levels, in a statistically significant manner. The same was noted when assessing the VEGF levels (the factor involved in neovascularisation of granular tissue).
The research also allowed analysing some of the most important cytoskeletal proteins which had modified their organisation after stimulation with cytokines, and returned to the basal distribution after treatment with MiS.
It can therefore be concluded that not only does the ASA device have an important anti-inflammatory effect, but it is also effective in controlling fibroblast activation induced by IL‐1β and TNF‐α, probably responsible for a detrimental effect on the inflammation’s evolution, which favours its persistence.
“Effect of NIR Laser Therapy by MLS‐MiS Source on Fibroblast Activation by Inflammatory Cytokines in Relation to Wound Healing”
S. Genah, F. Cialdai, V. Ciccone, E. Sereni, L. Morbidelli, M. Monici
Biomedicines 9, 307, 2021
L'accesso alla visualizzazione dei prodotti e al materiale informativo è riservato agli operatori del settore in ottemperanza alla legislazione vigente. ASA richiede di qualificarsi come operatore del settore per procedere con la navigazione.
Decreto Legislativo 24 febbraio 1997, n°46 Articolo 21
1. E' vietata la pubblicità verso il pubblico dei dispositivi che, secondo disposizioni adottate con decreto del Ministro della Sanità, possono essere venduti soltanto su prescrizione medica o essere impiegati eventualmente con l'assistenza di un medico o di altro professionista sanitario.
2. La pubblicità presso il pubblico dei dispositivi diversi da quelli di cui al comma 1 è soggetta ad autorizzazione del Ministero della Sanità. Sulle domande di autorizzazione esprime parere la Commissione di esperti prevista dall'articolo 6, comma 3, del decreto legislativo
30 dicembre 1992, n. 541, che a tal fine è integrata da un rappresentante del Dipartimento del Ministero della Sanità competente in materia di dispositivi medici e da uno del Ministero dell'Industria, del commercio e dell'artigianato.
Some of the contents of this website cannot be disclosed in the USA and its territories and possesions, for regulatory reasons. If you are a US resident, please click on the button here below and access ASA's distributor website for North America.